SUBSCRIBE
SUBSCRIBE
News   Drug Development

Dendreon Corporation Sees Positive Results From Provenge

November 10, 2006 | 
1 min read
NEW YORK, Nov 10 (Reuters) - Dendreon Corp. (DNDN.O: Quote, Profile, Research) said on Friday analysis of its Provenge immunotherapy for the treatment of advanced prostate cancer showed positive results.

>>> Discuss This Story

Clinical research Postmarket research
MORE ON THIS TOPIC
Insights
Inside the Race to Build the Next Generation of AI Drug Discovery Platforms
March 19, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Prohibition sign. Halftone hands cross their fingers in a no entry sign. Refusal, stop gesture. Rejection sign. Warning concept. Newspaper collage
FDA
Third FDA Rejection for Aldeyra’s Dry Eye Disease Drug Sends Shares Plummeting
March 17, 2026
 · 
2 min read
 · 
Heather McKenzie
Cambridge, USA - 8 July 2025. Pfizer office entrance with logo on a modern glass building, surrounded by greenery.
Breast cancer
Pfizer’s Ibrance Heir Reduces Risk of Death in Phase 2 Breast Cancer Test
March 17, 2026
 · 
1 min read
 · 
Annalee Armstrong
Abstract creative art collage, market declines in the stock market. The concept of collapse or bankruptcy.
Obesity
Rhythm’s Imcivree Fails Late-Stage Weight Loss Trial in Rare Obesities
March 17, 2026
 · 
2 min read
 · 
Tristan Manalac